Tumor acidity-activatable macromolecule autophagy inhibitor and immune checkpoint blockade for robust treatment of prostate cancer
Acta Biomaterialia · 2023-09 · 168 · 593-605
DOI: 10.1016/j.actbio.2023.07.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2023-09. Verfasst von Yiyao Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 51…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Prostatic Neoplasms. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Sun Yat-sen University, Medical Science and Technology Foundation of Guangdong Province, Science, Technology and Innovation Commission of Shenzhen Municipality.
Abstract (Originalsprache)
Immune checkpoint blockade (ICB) antibody such as anti-PD-L1 (aPD-L1) activates cytotoxic T cells (CTLs) to combat cancer, but they showed poor efficacy in prostate cancer (PCa). Lysosome-dependent autophagy is utilized by cancer cells to degrade their MHC-I and to lower their vulnerability to TNF-α and CTLs. Lysosomal pH-sensitive polymeric nanoparticle as a drug delivery carrier may also be a novel autophagy inhibitor to boost immunotherapy, but such an important effect has not been investigated. Herein, we developed a unique tumor acidity-activatable macromolecular nanodrug (called P-PDL1-CP) with the poly(2-diisopropylaminoethyl methacrylate) (PDPA) core and the conjugations of both aPD-L1 and long-chain polyethylene glycol (PEG) coating. The PDPA core was demonstrated to disturb lysosome to block the autophagic flux, thus elevating the cancer cell's MHC-I expression and vulnerability to the TNF-α and CTLs. Long-chain PEG facilitated a good tumor accumulation of P-PDL1-CP nanodrug. Furthermore, P-PDL1-CP nanodrug inhibited tumor autophagy, which synergized with aPD-L1 to promote the tumor-infiltrating CTLs and DCs maturation, to elevate intratumoral TNF-α and IFN-γ levels, and to elicit an anti-tumor immune memory effect in mice for PCa growth inhibition with low side effects. This study verified the synergistic anti-PCa treatment between autophagy inhibition and PD-L1 blockade and meantime broadened the application of pH-sensitive macromolecular nanodrug. STATEMENT OF SIGNIFICANCE: A macromolecular nanodrug, comprising the PDPA core and the surface conjugation of both aPD-L1 antibodies and long-chain PEG coating via a tumor acidity-labile α-carboxy-dimethylmaleic anhydride amine bond, was developed. Tumoral acidity triggered the release of aPD-L1 for immunotherapy. Meantime, the charge switch of the remanent nanodrug enhanced the cancer cell uptake of PDPA, which disturbed the lysosomes to inhibit autophagy. This advanced nanodrug promoted the tumor-infiltrating CTLs and DCs maturation, elevated the intratumoral TNF-α and IFN-γ levels, and elicited the robust anti-tumor immune memory effect. This study demonstrated that the pH-sensitive PDPA macromolecule could serve as a carrier for the aPD-L1 delivery and as an efficient autophagy inhibitor to boost the immunotherapy of prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, PR China.
- Nanomedicine Research Center, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, PR China.
- Nanomedicine Research Center, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, PR China. Electronic address: shuaixt@mail.sysu.edu.cn.
- Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, PR China. Electronic address: huangjsh55@mail.sysu.edu.cn.
- Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, PR China. Electronic address: pangjun2@mail.sysu.edu.cn.
Förderung
- Sun Yat-sen University
- Medical Science and Technology Foundation of Guangdong Province
- Science, Technology and Innovation Commission of Shenzhen Municipality
- Sanming Project of Medicine in Shenzen Municipality
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Lei, H., Yan, B., Zhang, S., Xu, B., Lin, M., Shuai, X., Huang, J., & Pang, J. (2023). Tumor acidity-activatable macromolecule autophagy inhibitor and immune checkpoint blockade for robust treatment of prostate cancer. Acta Biomaterialia, 168, 593-605. https://doi.org/10.1016/j.actbio.2023.07.018
Vancouver
Wang Y, Lei H, Yan B, Zhang S, Xu B, Lin M, et al. Tumor acidity-activatable macromolecule autophagy inhibitor and immune checkpoint blockade for robust treatment of prostate cancer. Acta Biomaterialia. 2023;168:593-605. doi:10.1016/j.actbio.2023.07.018
BibTeX
@article{Wang2023,
author = {Wang, Yiyao and Lei, Hanqi and Yan, Binyuan and Zhang, Shiqiang and Xu, Bin and Lin, Minzhao and Shuai, Xintao and Huang, Jinsheng and Pang, Jun},
title = {Tumor acidity-activatable macromolecule autophagy inhibitor and immune checkpoint blockade for robust treatment of prostate cancer},
journal = {Acta Biomaterialia},
year = {2023},
volume = {168},
pages = {593--605},
doi = {10.1016/j.actbio.2023.07.018}
}
EUVIMED